ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 135 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,008,282 | +457.7% | 916,620 | +528.6% | 0.00% | – |
| Q1 2024 | $180,807 | -66.9% | 145,812 | -72.0% | 0.00% | – |
| Q4 2023 | $546,924 | -70.7% | 520,880 | +90.9% | 0.00% | – |
| Q3 2023 | $1,868,824 | -53.8% | 272,821 | -30.0% | 0.00% | -100.0% |
| Q2 2023 | $4,042,080 | +68.4% | 389,786 | +31.4% | 0.00% | 0.0% |
| Q1 2023 | $2,399,834 | -56.1% | 296,642 | -14.6% | 0.00% | 0.0% |
| Q4 2022 | $5,469,944 | +82204.3% | 347,298 | -17.8% | 0.00% | -50.0% |
| Q3 2022 | $6,646 | +16.7% | 422,247 | +3.5% | 0.00% | +100.0% |
| Q2 2022 | $5,694 | -99.9% | 407,889 | +57.8% | 0.00% | 0.0% |
| Q1 2022 | $4,456,000 | +38.5% | 258,459 | +16.8% | 0.00% | 0.0% |
| Q4 2021 | $3,217,000 | -59.5% | 221,192 | -49.9% | 0.00% | -50.0% |
| Q3 2021 | $7,939,000 | +39.0% | 441,094 | +35.6% | 0.00% | +100.0% |
| Q2 2021 | $5,711,000 | +87.9% | 325,275 | +169.8% | 0.00% | 0.0% |
| Q1 2021 | $3,039,000 | +1687.6% | 120,582 | +358.4% | 0.00% | – |
| Q4 2020 | $170,000 | +150.0% | 26,307 | 0.0% | 0.00% | – |
| Q3 2020 | $68,000 | +19.3% | 26,307 | -25.1% | 0.00% | – |
| Q2 2020 | $57,000 | +128.0% | 35,112 | +45.8% | 0.00% | – |
| Q1 2020 | $25,000 | -70.9% | 24,086 | -47.3% | 0.00% | – |
| Q4 2019 | $86,000 | +87.0% | 45,709 | +9.0% | 0.00% | – |
| Q3 2019 | $46,000 | -87.0% | 41,942 | -74.0% | 0.00% | – |
| Q2 2019 | $353,000 | -39.1% | 161,212 | +66.5% | 0.00% | – |
| Q1 2019 | $580,000 | -37.1% | 96,836 | -22.4% | 0.00% | – |
| Q4 2018 | $922,000 | -33.5% | 124,780 | +30.7% | 0.00% | – |
| Q3 2018 | $1,386,000 | +0.4% | 95,438 | +38.1% | 0.00% | – |
| Q2 2018 | $1,380,000 | -20.8% | 69,101 | -30.5% | 0.00% | – |
| Q1 2018 | $1,742,000 | -1.4% | 99,422 | +38.8% | 0.00% | – |
| Q4 2017 | $1,766,000 | -71.8% | 71,612 | -70.5% | 0.00% | -100.0% |
| Q3 2017 | $6,266,000 | +7.5% | 242,755 | +12.9% | 0.00% | 0.0% |
| Q2 2017 | $5,831,000 | +50.7% | 215,028 | +65.8% | 0.00% | +100.0% |
| Q1 2017 | $3,868,000 | – | 129,723 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
| Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
| GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
| Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
| VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
| Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
| Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
| BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |